Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
1. Biodexa filed a CTA for the Serenta trial in Europe. 2. Trial targets familial adenomatous polyposis, a high-cancer-risk condition. 3. Serenta trial is approved in the US and now expanding to Europe. 4. Funding from CPRIT supports the development of eRapa. 5. Phase 3 trial results crucial for potential market entry of eRapa.